Merck Launches ChemisTwin, First Ever Digital Reference Materials Platform for Analytical Testing

ChemisTwin, the automation and calibration tool is easy to use and intuitive. This initiative seeks to contribute to advancing scientific research, product development, quality control, and regulatory compliance.

Merck, a leading science and technology company, has launched ChemisTwin, the first digital reference materials platform. This platform is designed to automatically analyse the purity, identification, and degradation of compounds in samples using calibrated algorithms and digital references.

This newly launched tool helps scientists in ensuring the quality and safety of medicines from the earliest stages of research and development through quality control and quality assurance testing with digital signatures for more than 1,500 reference materials.

ChemisTwin, the automation and calibration tool is easy to use and intuitive. This initiative seeks to contribute to advancing scientific research, product development, quality control, and regulatory compliance.

Sharing his views, Jean-Charles Wirth, head of science & lab solutions, life science business sector, Merck, said, “Increasing adoption of digital technologies, powered by high-quality data, is disrupting the life science industry. Being able to digitize reference materials for the first time is a giant step forward towards safeguarding the world’s medicines and consumer products.”

Accredited reference materials are fundamental to the extensive quality testing industry. These materials are essential for maintaining the precision, dependability, and consistency of measurements and analyses within the life science sector.

Moreover, they serve as standards or references for the identification and quantification of substances, guaranteeing the safety, absence of contaminants, and proper performance of pharmaceuticals and various other products, including water, food, and beverages.

Founded in 1668, Merck also known as Merck KGaA is one of the oldest pharmaceutical companies in the world. The company operates across healthcare, life science, and electronics. Further, it seeks to leverage science and technology to achieve lasting progress for mankind. Today, the company is rapidly advancing in research and development to deliver advanced health solutions across the world.

Merck Life Science Private Limited was incorporated in 1986 as a joint venture with Millipore Corporation, USA and became a 100% subsidiary of Millipore Corporation in 2009. Millipore was acquired by Merck Chemicals in 2010. Merck Life Sciences offers advanced tools, services, and expertise to researchers around the world. They offer one of the broadest portfolios in the industry for scientists and their innovations touch individuals globally.

In September this year, Merck entered two strategic collaborations to strengthen AI-driven drug discovery with BenevolentAI, London, UK, and Exscientia, Oxford, UK.

These partnerships sought to utilise AI-driven design and discovery capabilities, further advancing Merck's research efforts. Further, it is expected to generate multiple novel clinical development drug candidates with first-in-class potential, particularly in critical therapeutic areas of oncology, neurology and immunology.